Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

NCT02720367 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Cancer

Interventions

DRUG: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200

Sponsor

Taris Biomedical LLC